country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-184750

Copy Link Print Information

Anticancer agent 337

Anticancer agent 337 (compound 5n) is a topoisomerase I inhibitor. Anticancer agent 337 inhibits topoisomerase I activity in a concentration-dependent manner, suppresses cancer cell migration, induces apoptosis, and arrests the cell cycle at the G1 phase. Anticancer agent 337 can be used in the research of lung cancer, hepatocellular carcinoma, and cervical adenocarcinoma.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Formule: C₃₃H₄₂N₄O₂Se
Masse moléculaire:605.67

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Anticancer agent 337 Chemical Structure

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

Topoisomerase I

Voir tous les produits spécifiques à Isoform Topoisomerase :

In Vitro

Anticancer agent 337 (compound 5n) (48 h) potently inhibits the proliferation of A549, HepG2, and HeLa cancer cells with IC₅₀ values of 5.22 μM, 6.28 μM, and 3.62 μM, respectively, while exhibiting minimal toxicity to normal LO-2 hepatocytes^[1].
Anticancer agent 337 (10-100 μM; 30 min) inhibits human Topo I activity in a concentration-dependent manner, blocking supercoiled DNA relaxation at concentrations ranging from 10.0 μM to 100.0 μM^[1].
Anticancer agent 337 (100 μM; 30 min) acts as a Topo I poison at 100.0 μM, stabilizing the Topo I-DNA cleavage complex to induce DNA strand breaks, consistent with the mechanism of CPT (HY-16560)^[1].
Anticancer agent 337 (1.25-5 μM; 48 h treatment followed by 14-day culture) suppresses the long-term proliferation of A549 cells in a concentration-dependent manner, with stronger inhibition at 5.0 μM than the positive control CPT^[1].
Anticancer agent 337 (1.25-5 μM; 24 h, 48 h) inhibits the migration of A549 cells in a concentration-dependent manner over 24 h and 48 h, demonstrating anti-metastatic potential^[1].
Anticancer agent 337 (1.25-5 μM; 24 h) potently induces apoptosis in A549 cells in vitro in a concentration-dependent manner, with an 84.0% total apoptosis rate at 5.0 μM, which is significantly higher than that of the positive control CPT^[1].
Anticancer agent 337 (1.25-5 μM; 24 h) induces dose-dependent G1/G0 phase cell cycle arrest in A549 cells, with 74.36% of cells accumulating in G1 phase at a concentration of 5.0 μM^[1].
Anticancer agent 337 (1.25-5 μM; 48 h) induces concentration-dependent DNA double-strand breaks in A549 cells, with γ-H2AX foci levels at 5.0 μM comparable to those induced by the positive control CPT^[1].
Anticancer agent 337 (1.25-5 μM; 24 h) induces concentration-dependent mitochondrial dysfunction in A549 cells, reducing mitochondrial membrane potential at concentrations of 1.25 μM, 2.5 μM, and 5.0 μM^[1].
Anticancer agent 337 (1.25-5 μM; 12 h) induces concentration-dependent oxidative stress in A549 cells, significantly increasing intracellular ROS levels at concentrations of 1.25 μM, 2.5 μM, and 5.0 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

human A549 lung carcinoma cells
Concentration:

1.25, 2.5, 5 μM
Incubation Time:

48 h (treatment followed by 14-day culture)
Result:

Induced a concentration-dependent reduction in colony formation.
Showed stronger inhibitory effects on cell proliferation than the positive control CPT at 5 μM.

Apoptosis Analysis^[1]

Cell Line:

human A549 lung carcinoma cells
Concentration:

1.25-5 μM
Incubation Time:

24 h
Result:

Induced total apoptosis (early + late) in a concentration-dependent manner, with rates of 10.5%, 25.7%, and 84.0% at 1.25 μM, 2.5 μM, and 5 μM, respectively.
Induced significantly higher apoptosis than the positive control CPT (15.3% apoptosis rate) at 5 μM.

Cell Cycle Analysis^[1]

Cell Line:

human A549 lung carcinoma cells
Concentration:

1.25, 2.5, 5 μM
Incubation Time:

24 h
Result:

Induced dose-dependent G1/G0 phase cell cycle arrest.
Increased the proportion of G1-phase cells from 41.83% (control) to 74.36% at 5 μM.
Decreased the combined S and G2/M phase proportion from 58.17% to 25.82% at 5 μM.

Immunofluorescence^[1]

Cell Line:

human A549 lung carcinoma cells
Concentration:

1.25, 2.5, 5 μM
Incubation Time:

48 h
Result:

Induced a concentration-dependent accumulation of γ-H2AX foci, a marker of DNA double-strand breaks.
Induced DSB levels similar to the positive control CPT at 5 μM.

In Vivo

Anticancer agent 337 (compound 5n) (50-100 mg/kg; i.p.; single dose) exhibits an acceptable in vivo safety profile at a single intraperitoneal dose of 50.0 mg/kg in healthy KM mice, but causes acute toxicity and mortality at 100.0 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KM mice (female, 18-24 g)^[1]
Dosage:

50 mg/kg; 100 mg/kg
Administration:

i.p.; single dose
Result:

Exhibited normal growth with gradual weight gain over 14 days, no behavioral abnormalities, and histopathological examination of heart, liver, spleen, lungs, and kidneys showed no signs of necrosis, inflammation, or morphological abnormalities at 50 mg/kg.
Caused acute toxic reactions, resulting in mortality in 4 out of 8 treated mice at 100 mg/kg.

Chemical Information

Masse moléculaire 605.67
Formule C₃₃H₄₂N₄O₂Se
SMILES

O=C(NCCC[Se]C#N)CCC[C@]1([H])[C@@]2([H])[C@@]3([H])[C@@](CCCN3CCC2)([H])CN1CC4=CC=C(C(C5=CC=CC=C5)=O)C=C4
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Xiao J, et al. Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents. Bioorganic chemistry. 2026 Jun 27;180:110173. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Anticancer agent 337

Voir tous les produits spécifiques à Isoform Topoisomerase